Dear readers of ADxS.org, please forgive the disruption.

ADxS.org needs about $36850 in 2023. In 2022 we received donations from third parties of about $ 13870. Unfortunately, 99.8% of our readers do not donate. If everyone who reads this request makes a small contribution, our fundraising campaign for 2023 would be over after a few days. This donation request is displayed 18,000 times a week, but only 40 people donate. If you find ADxS.org useful, please take a minute and support ADxS.org with your donation. Thank you!

Since 01.06.2021 ADxS.org is supported by the non-profit ADxS e.V..

$16307 of $36850 - as of 2023-08-31
44%
I would like to donate via PayPal
More info about donations
ADxS.org Logo
ADxS.org Logo
Search Sitemap Donations Last Changes Deutsche Version
Register

Existing Account? Login

Header Image
Consequences

Sitemap

The ADxS.org project
Abstract of ADxS.org
Symptoms
Consequences
Origin
Stress
Neurological aspects
Diagnostics
Prevention
Treatment and therapy
This and That about ADHD
Tests and surveys
Forum

Consequences

ADHD not only has symptoms that are acutely manifested in the behavior of the affected person, but also long-term consequences.

1. Consequential risks of ADHD

ADHD sufferers have to accept massive restrictions in their quality of life.
Untreated / inappropriately treated ADHD has massive lifetime implications,12 e.g.:

1.1. Life expectancy shortened by 9 to 13 years

  • Life expectancy reduced by 9 to 13 years3

  • 1.27- to 4.6-fold premature mortality. Depending on the study, between 1.27-fold (boys and men),4 2.85-fold (girls and women),4 1.4-fold (children and adolescents), and more than 4.6-fold (in adults),5 especially from accidents.67891011121314

  • With the number of additional comorbidities, the likelihood of premature death increases up to 25-fold.515

  • 4.25-fold risk of premature mortality with first ADHD diagnosis in adulthood.4

  • 2.4-fold risk of suicide in ADHD overall, especially in women16 (up to 4.1-fold risk of suicide). Correspondingly higher in untreated ADHD.1718

  • Suicide rate increases19 by 2.3 times20 by 2.9 times21

  • Suicidal thoughts and suicide attempts increased22

    • Not, however, in veterans with ADHD23

  • 2-fold risk of falling victim to murder24

1.2. More frequent accidents and injuries

1.2.1. Injuries

  • Injuries increased25
    • By 41 % for young adults26
    • By 250 % for children and adolescents27
  • Risk of bone fractures
    • increased by 60 % for girls 28
    • increased by just under 40 % in boys 28
    • Stress fractures increased by 17%.29
  • Concussions twice as common in children aged 11 to 14 with ADHD30
  • Head injuries due to some types of accidents in ADHD to more than twice31 to more than three times as common32
  • Children with eye injuries were 3.5 times more likely to have ADHD than children without eye injuries.33
  • Intentional self-poisoning increased 4.65 times34

1.2.1. Traffic accidents and accident damage

  • 40% of drivers with ADHD had at least 2 crashes, compared with 6% of unaffected drivers.35
  • 60% of drivers with ADHD had an injury accident, compared to 17% of unaffected drivers.35
    • this is more likely to be due to comorbid ODD and/or CD. For ADHD itself, a meta-study found a 23% increased accident rate.36
  • The claim amount for drivers with ADHD was nearly three times the claim amount for unaffected drivers.35
  • Drivers with ADHD were three times more likely to lose their driver’s license than unaffected drivers. This could also result from an impaired ability to defend oneself in court due to disorganization.35
  • 2.74-fold risk of motor vehicle crashes resulting in injury among those aged 65 and older37

A meta-analysis of 16 studies showed:36

  • the accident risk for drivers with ADHD is increased by 23
  • this corresponds to the increase in risk from cardiovascular disease
  • ADHD sufferers seem to drive more often than non-affected persons, which is why the actual value is likely to be below the 23 %
  • the claim of an almost fourfold risk of accidents from a study by Barkley et al. (1993) is likely to be due to comorbid ODD and/or CD. It does not hold for ADHD itself.
  • ADHD sufferers are warned more often for speeding, but not more often for drunk or reckless driving

1.3. Higher crime and violence

  • 9 times the risk of ending up in prison due to crime38
  • Arrests increased by 105%39
    • ADHD sufferers are 6.4 times more likely to be perpetrators of domestic violence than non-affected individuals.40

Quite a few studies have found massively increased rates of ADHD in prison inmates.

  • Up to 72% of prison inmates in Asian, Western European, and North American countries have been diagnosed with ADHD, he said.41
  • 14 % to 45 % ADHD4243
  • 25 %44
  • 17.3%45 of juvenile inmates
  • 31 %46 of juvenile inmates
  • 25 % of all prisoners in USA47
  • 28% of all incarcerated persons in U.S48
  • 17.5% of 244 correctional inmates studied (n = 244)49
  • 27.6% of 146 sex offenders studied (n=146, WURS 90 pts)49
  • 22% of patients in forensic psychiatry (n = 86)50
  • 9.1% of 55 Irish inmates studied51
  • 17% of all young men serving time for minor to moderate offenses in Lithuania.52 The ADHD-affected inmates were younger and had greater behavioral problems in prison. None of them had previously received an ADHD diagnosis.
  • 20 to 30% of all young adult prison inmates.53

As a result, the crime rate among ADHD sufferers is massively increased.

  • Hyperactive individuals have significantly increased arrest rates:54
    • Adolescents (46% vs. 11%)
    • Adults (21% vs. 1%)
  • 19% of ADHD sufferers had committed crimes, 0% in control group55

Interestingly, amphetamines are the drugs most commonly used by ADHD-affected prison inmates.56 Amphetamine is known to be an active ingredient in highly effective ADHD medications.

A study of the correlation of ADHD symptoms and criminogenic thinking found that57

  • Inattention was consistent and strongly associated with criminogenic mindsets, especially with
    • Cutoff
    • Cognitive inertia
    • Discontinuity
  • Impulsivity was positively correlated with criminogenic thinking patterns, with
    • Power orientation
  • Hyperactivity was not associated with criminogenic thinking.

ADHD medication reduced crime rates among ADHD sufferers58

  • For men by 31
  • For women by 41

1.4. Comorbid health problems

1.4.1. Mental illness

  • Increased likelihood of inpatient psychiatric treatment. Among 166 psychiatric inpatients, 59% were found to have ADHD.59
1.4.1.1. Depression (up to 5.5 times)
  • 5.5-fold risk of a major depressive episode before adulthood. 50% of all ADHD sufferers have one.60
  • Depression increases61
  • 2.5-fold62 to 4-fold risk of depression in girls
  • ADHD in children increases the risk of depression in adolescence.63
1.4.1.2. Nervous system disorders (up to 5-fold)
  • Nervous system disorders (1.5 to 4.6 times the risk), mainly caused by environmental hazards, e.g.:
    • Sleep disorders
    • Epilepsy
    • Dementia
      • Parents of ADHD sufferers showed a 55% increased risk of Alzheimer’s disease or dementia in a Swedish cohort study. Grandparents showed an even smaller increase in risk.64 One study found a correlation between ADHD PRS and Alzheimer’s disease65
  • Up to 5-fold increased risk of neurodegenerative diseases, especially Lewy body dementia.66
1.4.1.3. Eating disorders (3.6-fold)
  • 3.6-fold risk of eating disorders in girls67
  • Obesity (2-fold risk)3
1.4.1.4. Anxiety disorders (up to 3.3 times)
  • 1.2 to 3.3 times the risk of anxiety disorders. Lifetime prevalence 10 - 15 % total population,68 12 to 50 % in ADHD18

1.4.2. Behavioral peculiarities

  • Increased risk behavior69

  • More often a victim of physical and non-physical sexual abuse70

1.4.3. Physical diseases

  • Increased risk for most physical diseases (34 [97 %] of 35 diseases studied), independent of sex71
1.4.3.1. Respiratory diseases (up to 3.2 times)
  • Respiratory diseases (2.4 to 3.2 times the risk), mainly genetic, e.g.:
    * Asthma
    * Chronic obstructive pulmonary disease
1.4.3.2. Infections (up to 2.8-fold)
  • Infections increased in childhood72
    - Salmonellosis (180% more frequent)
    - Acute respiratory infections (40% more common)
    - Acute gastroenteritis (30% more frequent)
    - Urinary tract infections (30% more frequent)
    - All anti-infectives were prescribed significantly more often to children with ADHD
    - The number of doctor visits was significantly higher in children with ADHD.
1.4.3.3. Risk of addiction (up to 2.3 times)
  • Alcohol consumption increased22
  • Smoking more often2273747561
    • 2.35-fold7677 to 8.61-fold risk of smoking78 ADHD-affected adults have a 50% increased risk of smoking (OR = 1.5)79 Conversely, young adult smokers are twice as likely to have ADHD.80
    • ADHD-affected youth have a doubled (OR = 2)79 to tripled77 risk of smoking
    • One study found no association between ADHD symptoms and smoking81
  • Marijuana use increased73
  • 1.77-fold risk of substance dependence (addiction)78
    The majority of research on ADHD and alcohol abuse finds a positive correlation.82
1.4.3.3. Birth complications in mothers with ADHD (up to 1.8-fold)

Among 45,737 pregnant women with ADHD compared with 42,916 women without ADHD, mothers with ADHD were found to have higher rates of almost every type of birth complication, most of which were 1.2 to 1.8 times more likely to occur.83

1.4.3.4. Risk of stroke (up to 1.4-fold)
  • Stroke risk increased84
    * Risk of ischemic stroke increased by 15%
    * Risk of large-artery atherosclerotic stroke increased by 40%

1.5. More teenage pregnancies

  • 2.3-fold risk of early pregnancy in untreated teens with ADHD. Teenage pregnancies are 27% more common with untreated ADHD. With treated ADHD, the risk decreased very significantly.85
  • 42 times as many maternities by age 20 as non-affected (Doubtful - data could not be verified so far)35

1.6. Educational disadvantages

  • Poorer educational opportunities61
    • University degrees 27% less common39
    • School-leaving qualifications 11 % less frequent39
    • Lower educational attainment22
    • Rare bachelor’s degree86
    • More school absenteeism (diagnosed ADHD, including ADHD treated with medication)87
      • Up to 10 years: 7
      • 11 to 14 years: 24 %
      • From 15 years: 23 %
    • More school expulsions (diagnosed ADHD, including ADHD treated with medication)87
      • 4.97-fold in the quintile with highest deprivation
      • 14.75-fold in the quintile with lowest deprivation
      • 5.4 times for boys
      • 9.42 times for girls
    • Increased special education needs (diagnosed ADHD, including ADHD treated with medication)87
    • Mental health 52.85 times
    • Social, emotional and behavioral disorders 19.97 times
    • Autism spectrum disorder 13.72-fold
    • Learning disability 8.10-fold
    • Physical health 6.97 times
    • Physical or motor impairment 6.28 times
    • Learning difficulties 5.44 times
    • Communication problems 4.78 times
    • Sensory impairment 3.62-fold
    • ADHD causes decreased emotional school engagement over the long term, which is further moderated by student-teacher conflict.88

1.7. Professional disadvantages and loss of income

Significant occupational disadvantage is a common consequence of ADHD86

  • Job change increased by 5939
  • Fewer full-time jobs, more part-time jobs
    • Women (in Japan) with ADHD appear even more likely to have only a part-time job than men with ADHD.89
  • Employment rate reduced by 2839
  • 3 times the risk of losing a job35
  • Higher layoff rate 1.1 vs 0.3 jobs/time90
  • Frequent job changes 2.7 vs 1.3 jobs/ 2- 8 yrs SE90
  • Worse evaluations in the workplace90
  • Not in employment, education, or training 6 months after leaving school87
    • Total 1.39 times
    • Boys 1.40 times
    • Girl 1.59 times

1.8. Reduced quality of life

  • Reduced quality of life (QoL)69
    • Health-related QoL significantly reduced91
  • 4-fold increased risk of decreased length growth and weight gain at 8 and 10 years. Stimulant treatment increased this risk.92
  • ADHD in childhood predicts emotional problems later in life. These are genetically mediated.93
  • Life dissatisfaction is a typical consequence of ADHD.

According to a study with n = 1000 participants, ADHD in adulthood leads to a significant reduction in life satisfaction (Quality of Life).94 In the domains

  • Family life
  • Partnership
  • Social life
  • Integration in society
  • Health and fitness
  • Professional life
  • Achieving life goals

aDHD sufferers scored on average about 20% worse than non-affected persons.

Adults with the highest 10% of ADHD symptom expression according to ADHD-E were 4.10 times more likely to experience distress from general life dissatisfaction and 3.3 times more likely to experience distress from lack of social support than unaffected adults.9596

1.9. Divorces / separations more often

  • Divorces
    • Increased by 8739
    • Women (in Japan) with ADHD appear to have even higher divorce rates than men with ADHD.89
  • 3 to 5 times the risk of separations and divorces18

2. Protective effect through ADHD treatment

Adults who received individualized ADHD therapy between the ages of 6 and 10 were found 18 years later:97

  • An improvement in ADHD symptoms that corresponded to the follow-up after 8 years
    • 18% no longer had an ADHD diagnosis
    • 55% had partial remission; of these:
      • ADHD-I 33 %
      • ADHD-HI 13 %
      • ADHD-C 54 %
    • 27% further had an ADHD diagnosis; of these:
      • ADHD-I 67 %
      • ADHD-HI 17 %
      • ADHD-C 17 %
    • Functional impairment in terms of
      • Finance 28 %
      • Daily responsibilities 28 %
      • Community activities 23 %
      • Learning/acquiring new learning content 21 %
  • Worse school / professional results than expected
    • School and professional qualifications
      • As often as in total population
      • Significantly worse grades
      • Much less likely to have a high school diploma / university entrance qualification than the general population
    • Increased unemployment
      • Currently unemployed: 17 %
        • Approximately 30% more likely to be unemployed than total population (study compares to 2011, when unemployment was 30% higher than 2019)
      • 25 % were unemployed for more than one year
      • 52% have been unemployed once in the last few years
  • More frequent contact with judicial system than expected
    • Criminal judgments 33 %
  • Health impairments, comorbidities
    • Threefold rate of externalizing or internalizing disorders
      • Three and a half times the rate of medication for mental health problems
    • 27% had a personality disorder according to DSM-IV
      • Antisocial personality disorder 12%, RR 6.8 (about 6 times more common; total population: 2%)
      • Avoidant personality disorder RR 2.0 (twice as frequent)
      • Schizoid personality disorder RR 2.0 (twice as frequent)
      • Paranoid personality disorder RR 1.3 (30% more frequent)
    • Addiction problems
      • Drug use: 15 %; highly frequent
      • Smoking slightly more often
      • Alcohol slightly more often
    • Weight problems
      • Overweight one and a half times more common than in total population
      • Obesity 30% more frequent than in total population
    • Chronic pain
      • Children with ADHD showed a prevalence of chronic pain of up to 66% (at least weekly pain for more than 3 months). Stimulant treatment decreased the rate of chronic pain. Another study found decreased pain perception in adolescents with ADHD, which disappeared with stimulant treatment.98
  • Several social outcomes were favorable
    • Long-term relationship/marriage: 63 %
  • Low life satisfaction, especially in the areas of
    • Health
    • Profession/Career
    • Leisure/recreational activities
    • Own children
    • Own person
    • Sexuality
    • Relations with others
    • Overall life satisfaction

ADHD medications reduce the risks of ADHD symptoms and sequelae. According to a metastudy, medication with stimulants reduces the aforementioned risks by 9% to 59%99

A metastudy of 40 studies found a robust protective effect of ADHD medications in relation to100

  • Mood disorders
  • Suicidality
  • (Car) accidents
  • Injuries
  • Traumatic brain injuries
  • Education and academic outcomes. Indifferent, on the other hand:101
  • Substance Abuse
  • Crime

Stimulants reduced the risk of suicide attempts by in several large studies in ADHD:102

  • 11.6 % (in all age groups)103
  • 19 %104
  • 42 %105
  • 59 % if taken for 3 months and half a year106
  • 72 % if taken for more than half a year106
  • Methylphenidate for ADHD was associated with a reduction in previously significantly increased suicide risk after 90 days.107
  • Other ADHD medications (non-stimulants) showed no or very little reduction in suicidality, e.g., 4%104

ADHD medication reduces accident incidence in affected boys and girls, as children and as adolescents.108109 by 43%110 and traumatic brain injury reduced by 49%111 to 66%.112

MPH reduced all-cause mortality by 20% in children with ADHD. Delayed use of MPH correlated with a 5% increase in mortality. Long-term use reduced all-cause mortality by 16%.113
No increased mortality was observed with the use of ADHD medications (stimulants or atomoxetine).114

ADHD medications reduce the risk of depression:115

  • 3 years after ingestion by 40
  • during the intake by 20

Any medication treatment for ADHD reduced the risk of

  • of fractures in total116

Treatment of ADHD with methylphenidate reduced the risk of

  • of stress fractures (fatigue fractures)
    • by 22.4%, although this figure was even lower than for non-affected persons.117
    • to 16 % less than for non-affected persons29
  • of trauma fractures (accidental fractures)
    • by 23% when taking MPH for at least 180 days118
    • to the same value as for non-affected persons29
    • ADHD sufferers treated with non-stimulants doubled the risk increase for bone fractures to 37% compared to the risk of non-affected individuals compared to the risk increase of all ADHD sufferers, which was 17% higher than non-affected individuals29
  • Of unintentional injuries by 15%119 or with an effect size of 0.88120
  • Of brain trauma by 73119
  • From poisoning121
  • Of injury-related emergency admissions by 9%122
  • of burns in adolescents with ADHD123
    • by 57% with MPH use for 90 days and longer by
    • by 30 % if MPH has been taken for less than 90 days by
  • from traffic accidents
    • for men by 38 % to 40124125
    • for women by 42125
    • serious traffic accidents (for men) by 50%124
  • of sexually transmitted diseases
    • only for men by 30 to 40126
  • of teenage pregnancies85

ADHD sufferers who were not treated with MPH were more likely to be victims of bullying/cyberbullying (physical victimization, isolation, destruction of property by others, and sexual victimization), more likely to destroy others’ things, and more likely to exhibit bullying behaviors (perpetrator-side).127

ADHD medications reduce the risk for sufferers,

  • to start smoking.77
  • to smoking, by 50128
  • for substance abuse by 31%.129

ADHD medications do not increase the risk for affected individuals:130

  • for alcohol abuse or dependence (11 studies, over 1300 participants)
  • for nicotine abuse or dependence (6 studies, 884 participants)
  • for cocaine abuse or dependence (7 studies, 950 participants)
  • for cannabis abuse or dependence (9 studies, over 1100 participants) did not increase (Humphreys et al., 2013).

ADHD medications reduce for sufferers

  • the crime rate58131
    • For men by 31
    • For women by 41

ADHD medications improve academic performance:

  • Three months of treatment with ADHD medications produced132
    • a grade improvement of more than nine points (scale: 0 to 320)
    • a 20% reduction in the risk of not receiving a recommendation for higher secondary education
  • ADHD sufferers’ test scores during the time they were taking medication were 4.8 points (scale: 1 to 200) higher than during the time they were not taking medication.133
  • Discontinuation of AD(HS medications correlated with a small significant decrease in grade point average134

Medication significantly mitigates the deterioration in health-related quality of life caused by ADHD.91
One meta-analysis found worsening quality of life when medications were discontinued in children and adolescents, but not in adults.135

How many affected individuals would need long-term treatment with MPH to avoid any of the following long-term consequences of untreated ADHD?136 The results were independent of gender:

  • 3 affected persons treated = 1 class repetition avoided
  • 3 treated affected = 1 avoided Oppositional Deficit Behavior
  • 3 affected persons treated = 1 avoided behavior disorder (conduct disorder)
  • 3 treated sufferers = 1 avoided anxiety disorder (with 2 impact types)
  • 4 affected persons treated = 1 major depression avoided
  • 4 victims treated = 1 serious car accident avoided (in simulation)
  • 5 affected persons treated = 1 bipolar disorder avoided
  • 6 affected persons treated = 1 smoker avoided
  • 10 persons treated = 1 addiction avoided

3. Financial consequences of ADHD

3.1. Treatment costs for ADHD

Treatment costs are the pure costs of therapy, medication, and doctor visits for the purpose of ADHD diagnosis and ADHD treatment.

The annual cost of drug treatment, including the cost of physician visits and laboratory tests, was estimated to range from $1,710 to $2,567 in 2004.137

3.2. Health care costs for ADHD

Health care costs include not only the direct treatment costs of ADHD itself, but also the additional medical costs for comorbidities resulting from ADHD (e.g., addiction problems) and the increased risk of accidents.

A 2016 Danish cohort study identified €2,636 higher annual health care costs for ADHD sufferers (€4,868 instead of €1,912 = 2.55 times).138
In addition, there was a further €477 increase in annual health care costs for partners of ADHD sufferers.

  • More than 2 times health care costs139

A meta-study for Europe between 1990 and 2013 calculated annual health care costs for ADHD of EUR 2,022 to EUR 2,390 per affected child/adolescent with ADHD.140 Added to this, health care costs for family members attributable to caring for an ADHD child/adolescent ranged from EUR 1339 to EUR 1826 per affected person.

For 1999 to 2001, higher annual health care costs were found among ADHD sufferers in the United States:141

  • doubled total medical costs ($5,651 vs. $2,771), including
    • outpatient costs ($3,009 vs. $1,492)
    • inpatient costs ($1,259 vs. $514)
    • Prescription drug costs ($1,673 vs. $1,008)

Per adult ADHD sufferer, annual total societal incremental health care costs of $1,635 were cited for 2018.142

Children with ADHD in Fleming (Belgium) required more intensive health care than their unaffected siblings in 2002. The utilization of medical services was:143

  • General practitioner (60.3 % vs. 37.4 %)
  • Specialist (50.9 % vs. 12.9 %)
  • Emergency room (26% vs. 12.1%)
  • Hospital admissions (14% vs. 8.4%)
    The annual health care costs for a child with ADHD were 6 times those of the unaffected sibling (588 EUR vs. 92 EUR). Public costs were doubled (779 EUR compared to 371 EUR).

Primary school children with hyperactivity incurred 17.6 times higher average annual costs (£562 rather than £30) across all domains (except nonmental health costs). Costs were consistently explained by male gender and, for some cost codes, by conduct disorder.144 It is likely that externalizing disorders such as ODD and CD contributed in their own right.

3.3. Relative costs in ADHD

Relative costs are the costs incurred by the parent or caregiver for the additional expense resulting from the individual’s ADHD.

A 2016 Danish cohort study identified €7,997 in annual additional direct and indirect costs per partner of an ADHD sufferer.138

One study calculated 5 times the direct annual family costs (“related to caregiver burden”) excluding treatment costs and indirect costs for ADHD sufferers aged 14 to 17.145

A meta-study for Europe between 1990 and 2013 calculated total annual costs of ADHD of 9,860 euros per child and 14,483 euros per adolescent with ADHD.140 Of this, productivity losses of family members accounted for 22% to 14%.

For adult ADHD sufferers, annual total societal incremental costs of $14,092 per adult were cited for 2018.142
Caregivers of adults with ADHD require an additional 0.8 hours per week for ADHD-related care compared to adults in the U.S. general population.146147 This results in an additional annual cost of $6.6 billion.

A meta-study of 19 studies identified total annual costs of ADHD in the U.S. (in 2010 dollars) ranging from $176 billion to $309 billion (1.17% to 2.05% of U.S. GDP).148 Of this, spillover costs borne by family members of individuals with ADHD accounted for $33 billion to $43 billion (0.22% to 0.29% of U.S. GDP).

3.4. Education costs for ADHD

A meta-study for Europe between 1990 and 2013 calculated total annual costs of ADHD of 9,860 euros per child and 14,483 euros per adolescent with ADHD.140 Of this, education costs accounted for 62% and 42%, respectively.

A meta-study of 19 studies identified total annual costs of ADHD in the U.S. (in 2010 dollars) between $176 billion and $309 billion (1.17% to 2.05% of U.S. GDP):148

  • for adults: $105 billion to $194 billion (0.7% to 1.29% of U.S. GDP)
    • especially productivity and income losses ($87 billion to $138 billion) (0.58% to 0.92% of U.S. GDP)
  • for children/youth: $38 billion to $72 billion (0.25% 0.48% of U.S. GDP)
    • especially health care: $21 billion - $44 billion (0.14% 0.29% of U.S. GDP)
    • of which education accounted for: $15 billion - $25 billion (0.1% to 0.17% of U.S. GDP)
  • Spillover costs borne by family members of individuals with ADHD: $33 billion to $43 billion (0.22% to 0.29% of U.S. GDP)

3.5. Increased social benefits

A 2016 Danish cohort study identified more frequent receipt of social benefits (sick pay or disability pension) by ADHD sufferers and their partners.138

3.6. Indirect damage caused by ADHD

3.6.1. Increased work absenteeism, unemployment, disability

For adult ADHD sufferers, annual total societal incremental costs of $14,092 per affected adult were cited for 2018.142
Of this amount

  • Additional unemployment costs: 54.4 % (7,666 USD / person affected)
    • Adult males with ADHD are 2.1 times more likely to be unemployed than non-affected individuals. Their unemployment rate is thus increased by 22.1 percentage points.
    • Adult women with ADHD are 1.3 times more likely to be unemployed than those not affected. Their unemployment rate is thus increased by 9.7 percentage points.
    • The annual incremental cost in the U.S. is $66.8 billion ($55.8 billion for men and $11 billion for women with ADHD). This is equivalent to 0.325% of GDP.
  • Productivity losses: 23.4 % (3,298 USD / affected person)149
    • 13.6 Working days ADHD-related absenteeism
    • 21.6 working days ADHD lost during attendance
    • The 35 days of lost productivity were distributed among
      • Workers: 55.8 days
      • Service workers: 32.6 days
      • Technician: 19.8 days
      • Skilled worker: 12.2 days
    • Lost productivity costs due to ADHD of $28.8 billion ($19.9 billion for men and $8.9 billion for women with ADHD). This is equivalent to 0.14% of GDP.

A Swedish registry study from 1998 to 2008 found in ADHD sufferers:150

  • 12.19 days more unemployment (252 working days would be 4.84%)
  • 19 times the probability of receiving a disability pension
    • Incapacities were largely explained by comorbid mental retardation and developmental disability, so are limited to improvement through more consistent treatment.

A rather small German study found unemployment to be 24.8% higher.151

3.6.2. Premature mortality

For adult ADHD sufferers, annual total societal incremental costs of $14,092 per adult were cited for 2018.142
Adults with ADHD have a doubled annual mortality rate (primarily due to increased rates of traffic and other accidents.152
This results in a total societal productivity loss of about $3.2 billion in 2018 (0.016% of 2018 GDP).

ADHD sufferers are 1.7 times more likely to have at least one accident:153

  • Children (28% vs. 18%)
  • Adolescents (32% vs. 23%)
  • Adults (38% vs. 18%)
    Follow-up costs for ADHD sufferers were increased only in adults ($483 vs $146 = 3.3-fold).

Some studies only look at the cost to the health care system and therefore are not adequate to describe the economic impact of ADHD.

  • No current figures exist for Germany. Older studies, which at best still have historical value, put the health care costs for ADHD in Germany in 2002 at €142,000,000 (€630/patient, or 225,000 affected persons. Considering the actual number of cases, the cost is considerably higher.)154 and in 2003 to 230,000,000 €in total.155 These figures included only treatment costs
  • One study found a total burden (“economic burden”) of $47.55 million among 69,353 diagnosed ADFH)S sufferers in Korea in 2012, representing $684 per sufferer and 0.004% of Korea’s GDP (gross domestic product) in 2012.156

3.6.3. Income deficits in ADHD

3.6.3.1. Reduced income

A long-term study over 20 years on 604 subjects showed that ADHD sufferers have a lower net income and greater financial dependence on their parents at the age of 30 than non-affected persons. This is true even when DSM criteria are no longer met. This deficit persists throughout life, resulting in $1.27 million lower expected lifetime income for males and up to 75% lower net worth at retirement than for unaffected individuals.157 In addition, ADHD-affected adults, if undiagnosed and untreated in childhood, earn significantly lower incomes than their unaffected twins and incur €20,000 higher costs per person per year158

A Swedish registry study from 1998 to 2008 found a 17% lower annual income among ADHD sufferers.150

American ADHD sufferers achieved fewer academic milestones beyond high school in 2003. ADHD-affected individuals were 42.3% less likely to have a full-time job, at 34%, than were nonaffected individuals, at 59%. Except for 18- to 24 -year-olds, mean household income was significantly reduced, regardless of academic achievement or personal characteristics. The national labor productivity loss associated with ADHD was estimated to be $67 billion to $116 billion (0.58% to 1.01% of U.S. GDP), assuming a prevalence of 2.3%.159
Income with ADHD in 2003 was:

  • Men: $45,645 vs. $54,399 (16.1% less)
  • Women: $37,607 vs. $49,738 (24.4% less)

With current prevalence figures of 5% for adults, this would be more than double. The consumer price index in the U.S. increased by 40% from 2003 to 2020. Assuming income and GDP had increased at the same rate, this would result in $183 to $322 billion (0.87% to 1.54% of GDP) in 2020.

A 2016 Danish cohort study identified lower earned income among ADHD sufferers in the five years prior to initial diagnosis.138

ADHD-affected adults, if undiagnosed and untreated in childhood, earned significantly lower incomes than their unaffected twins and paid less in taxes158

3.6.3.2. Tax and social security contributions not due from reduced income

So far, we know of only one study that calculated the resulting lost tax and social security contributions for Germany.
The German net tax and social security revenue of a non-affected person born in 2010 was found to be €80,000 higher than that of a non-treated ADHD person. ADHD interventions that improved educational attainment resulted in fiscal benefits through higher lifetime tax revenues.
For every euro spent on a new ADHD intervention, €1.39 in discounted net tax revenue and €3.02 in discounted gross tax revenue was calculated160
Converted to untreated adults in Germany and to 2020 values, we have calculated annual losses in net tax and social contribution revenues of EUR 5.916 billion. This corresponds to 1.63% of the federal budget.
This does not include savings from

  • reduced crime
    • eUR 111 million saved in prison costs annually
    • eUR 500 million in reduced damage from crime annually
  • reduced premature mortality: EUR 580 million annually
  • Relative costs: EUR 2 billion annually
  • Productivity losses in the workplace: EUR 11 billion annually

3.7. Total economic cost

One study cites $182,000 (as of 2015) higher costs from medical care, education, and crime consequences per ADHD case persisting into adulthood in the United States.161
An Australian study named total social and economic costs of ADHD of between $8.40 and $17.44 billion, with a cost per affected person of $15,664 per year (2018/2019).162 Of the total costs, the following accounted for

  • Productivity costs 81 %
  • Carrying losses 11 %
  • Costs for the health care system 4
    The loss of well-being was substantial, valued at $5.31 billion.

A 2016 Danish cohort study identified €22,721 in annual additional direct and indirect costs per ADHD sufferer (as of 2016).138
Adult ADHD sufferers accounted for €23,072 per year.

Another Danish study of same-sex twins showed for adults with ADHD, if undiagnosed and untreated in childhood163

  • higher total annual costs of €20,134 than for his siblings (as of 2010)
  • a significantly lower disposable income
  • lower taxes paid
  • higher receipt of state benefits
  • higher costs for health and social care
  • higher crime rate

Two American studies name the annual total societal ADHD-related additional costs at $6,799 per child ($19.4 billion) and $8,349 per adolescent ($13.8 billion) (as of 2017/2018).164 The costs were distributed among

  • Education costs (59.9% for children, 48.8% for youth)
  • direct health care costs (25.9% for children, 29.0% for adolescents)
  • Care costs (14.1% for children, 11.5% for youth).

One study identified $14,576 per ADHD sufferer (as of 2005) with a range of estimates between $12,005 and $17,458.165

  1. Steinhausen, Sobanski in Steinhausen, Rothenberger, Döpfner (2010): Handbuch AD(H)S, Kohlhammer, Seite 158 ff und 165 ff with several references ↥

  2. Leffa, Torres, Rohde (2018): A Review on the Role of Inflammation in Attention-Deficit/Hyperactivity Disorder. Neuroimmunomodulation. 2018;25(5-6):328-333. doi: 10.1159/000489635. with several references ↥

  3. Barkley (2019): ADHS wirkt sich auch auf die Lebenserwartung aus. Gastbeitrag. Ärzteblatt Rheinland-Pfalz 11/2019 ↥ ↥

  4. Dalsgaard, Østergaard, Leckman, Mortensen, Pedersen (2015): Mortality in children, adolescents, and adults with attention deficit hyperactivity disorder: a nationwide cohort study, The Lancet, Volume 385, Issue 9983, 2015, Pages 2190-2196, ISSN 0140-6736, https://doi.org/10.1016/S0140-6736(14)61684-6. n = 1,92 Millionen ↥ ↥ ↥

  5. Sun, Kuja-Halkola; Faraone, D’Onofrio, Dalsgaard, Chang, Larsson (2019): Association of Psychiatric Comorbidity With the Risk of Premature Death Among Children and Adults With Attention-Deficit/Hyperactivity Disorder. JAMA Psychiatry. doi:10.1001/jamapsychiatry.2019.1944, n = 2675615 ↥ ↥

  6. Shem-Tov, Chodick, Weitzman, Koren (2019): The Association Between Attention-Deficit Hyperactivity Disorder, Injuries, and Methylphenidate. Glob Pediatr Health. 2019 May 5;6:2333794X19845920. doi: 10.1177/2333794X19845920 ↥

  7. DiScala, Lescohier, Barthel, Li (1998): Injuries to Children With Attention Deficit Hyperactivity Disorder. Pediatrics, December 1998, VOLUME 102 / ISSUE 6 ↥

  8. Grigorian, Nahmias, Dolich, Barrios, Schubl, Sheehan, Lekawa (2019): Increased risk of head injury in pediatric patients with attention deficit hyperactivity disorder. J Child Adolesc Psychiatr Nurs. 2019 Jul 21. doi: 10.1111/jcap.12246. ↥

  9. Romo, Sweerts, Ordonneau, Blot, Gicquel (2019): Road accidents in young adults with ADHD: Which factors can explain the occurrence of injuries in drivers with ADHD and how to prevent it? Appl Neuropsychol Adult. 2019 Jul 16:1-6. doi: 10.1080/23279095.2019.1640697. ↥

  10. Kittel-Schneider, Wolff, Queiser, Wessendorf, Meier, Verdenhalven, Brunkhorst-Kanaan, Grimm, McNeill, Grabow, Reimertz, Nau, Klos, Reif (2019): Prevalence of ADHD in Accident Victims: Results of the PRADA Study. J Clin Med. 2019 Oct 8;8(10). pii: E1643. doi: 10.3390/jcm8101643. ↥

  11. Curry, Yerys, Metzger, Carey, Power (2019): Traffic Crashes, Violations, and Suspensions Among Young Drivers With ADHD. Pediatrics. 2019 Jun;143(6). pii: e20182305. doi: 10.1542/peds.2018-2305. ↥

  12. Raman, Engelhard, Kollins (2019): Driving the Point Home: Novel Approaches to Mitigate Crash Risk for Patients With ADHD. Pediatrics. 2019 May 20. pii: e20190820. doi: 10.1542/peds.2019-0820. ↥

  13. Catalá-López, Hutton, Page, Driver, Ridao, Alonso-Arroyo, Valencia, Macías Saint-Gerons, Tabarés-Seisdedos (2021): Mortality in Persons With Autism Spectrum Disorder or Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-analysis. JAMA Pediatr. 2022 Feb 14:e216401. doi: 10.1001/jamapediatrics.2021.6401. PMID: 35157020. METASTUDY ↥

  14. Barkley, Dawson (2022): Higher Risk of Mortality for Individuals Diagnosed With Autism Spectrum Disorder or Attention-Deficit/Hyperactivity Disorder Demands a Public Health Prevention Strategy. JAMA Pediatr. 2022 Feb 14:e216398. doi: 10.1001/jamapediatrics.2021.6398. PMID: 35157011. ↥

  15. Roy, Garner, Epstein, Hoza, Nichols, Molina, Swanson, Arnold, Hechtman (2019): Effects of Childhood and Adult Persistent Attention-Deficit/Hyperactivity Disorder on Risk of Motor Vehicle Crashes: Results From the Multimodal Treatment Study of ADHD. J Am Acad Child Adolesc Psychiatry. 2019 Aug 22. pii: S0890-8567(19)31458-3. doi: 10.1016/j.jaac.2019.08.007. ↥

  16. Yeh, Westphal, Hu, Peterson, Williams, Prabhakar, Frank, Autio, Elsiss, Simon, Beck, Lynch, Rossom, Lu, Owen-Smith, Waitzfelder, Ahmedani (2019): Diagnosed Mental Health Conditions and Risk of Suicide Mortality. Psychiatr Serv. 2019 Sep 1;70(9):750-757. doi: 10.1176/appi.ps.201800346. ↥

  17. Fitzgerald, Dalsgaard, Nordentoft, Erlangsen (2019): Suicidal behaviour among persons with attention-deficit hyperactivity disorder. Br J Psychiatry. 2019 Jun 7:1-6. doi: 10.1192/bjp.2019.128. n = 2,9 Millionen ↥

  18. Häge (2018): Psychostimulanzien und medikamentöse Behandlung der ADHS; Curriculum Entwicklungspsychopharmakologie; Potsdam, den 13.09.2018 ↥ ↥ ↥

  19. Friend (2019): Attention deficit hyperactivity disorder was associated with increased risk of suicidal behaviour. Arch Dis Child Educ Pract Ed. 2019 Dec 16. pii: edpract-2019-318308. doi: 10.1136/archdischild-2019-318308. ↥

  20. Gomes, Soares, Kieling, Rohde, Gonçalves (2019): Mental disorders and suicide risk in emerging adulthood: the 1993 Pelotas birth cohort. Rev Saude Publica. 2019 Oct 21;53:96. doi: 10.11606/s1518-8787.20190530012356. eCollection 2019. n = 3.781 ↥

  21. James, Lai, Dahl (2004): Attention deficit hyperactivity disorder and suicide: a review of possible associations. Acta Psychiatr Scand. 2004 Dec;110(6):408-15. doi: 10.1111/j.1600-0447.2004.00384.x. PMID: 15521824. REVIEW ↥

  22. Jaisoorya, Desai, Nair, Rani, Menon, Thennarasu (2019): Association of Childhood Attention Deficit Hyperactivity Disorder Symptoms with Academic and Psychopathological Outcomes in Indian College Students: a Retrospective Survey. East Asian Arch Psychiatry. 2019 Dec;29(124):124-128. doi: 10.12809/eaap1771. n = 5.145 ↥ ↥ ↥ ↥

  23. Bjork, Shull, Perrin, Shura (2022): Suicidal ideation and clinician-rated suicide risk in veterans referred for ADHD evaluation at a VA Medical Center. Psychol Serv. 2022 Apr 14. doi: 10.1037/ser0000659. PMID: 35420862. ↥

  24. Chen, Chan, Wu, Lee, Lu, Liang, Dewey, Stewart, Lee (2019): Attention-Deficit/Hyperactivity Disorder and Mortality Risk in Taiwan. JAMA Netw Open. 2019 Aug 2;2(8):e198714. doi: 10.1001/jamanetworkopen.2019.8714. ↥

  25. Libutzki B, Neukirch B, Kittel-Schneider S, Reif A, Hartman CA (2022): Risk of accidents and unintentional injuries in men and women with ADHD across the adult lifespan. Acta Psychiatr Scand. 2022 Dec 4. doi: 10.1111/acps.13524. PMID: 36464800. ↥

  26. Jernbro, Bonander, Beckman (2019): The association between disability and unintentional injuries among adolescents in a general education setting: Evidence from a Swedish population-based school survey. Disabil Health J. 2019 Sep 12:100841. doi: 10.1016/j.dhjo.2019.100841. ↥

  27. Jin, Chwo, Chen, Huang, Huang, Chung, Sun, Lin, Chien, Wu (2022): Relationship between Injuries and Attention-Deficit Hyperactivity Disorder: A Population-Based Study with Long-Term Follow-Up in Taiwan. Int J Environ Res Public Health. 2022 Mar 29;19(7):4058. doi: 10.3390/ijerph19074058. PMID: 35409742; PMCID: PMC8998513. n = 9.010 ↥

  28. Guo NW, Lin CL, Lin CW, Huang MT, Chang WL, Lu TH, Lin CJ (2016): Fracture risk and correlating factors of a pediatric population with attention deficit hyperactivity disorder: a nationwide matched study. J Pediatr Orthop B. 2016 Jul;25(4):369-74. doi: 10.1097/BPB.0000000000000243. PMID: 26523534. n = 7.200 ↥ ↥

  29. Zhang, Shen, Yan (2021): ADHD, stimulant medication use, and the risk of fracture: a systematic review and meta-analysis. Arch Osteoporos. 2021 Jun 2;16(1):81. doi: 10.1007/s11657-021-00960-3. PMID: 34076749. REVIEW ↥ ↥ ↥ ↥

  30. Iverson, Kelshaw, Cook, Caswell (2020): Middle School Children With Attention-Deficit/Hyperactivity Disorder Have a Greater Concussion History. Clin J Sport Med. 2020 Feb 6:10.1097/JSM.0000000000000773. doi: 10.1097/JSM.0000000000000773. PMID: 32032165. n = 1.037 ↥

  31. Pakyurek, Badawy, Ugalde, Ishimine, Chaudhari, McCarten-Gibbs, Nobari, Kuppermann, Holmes (2022): Does attention-deficit/hyperactivity disorder increase the risk of minor blunt head trauma in children? J Child Adolesc Psychiatr Nurs. 2022 Aug 13. doi: 10.1111/jcap.12390. PMID: 35962779. n = 3.700 ↥

  32. Beyoglu, Erdur (2022): Evaluation of the Relationship Between Head Trauma and Attention-Deficit/Hyperactivity Disorder in Primary School Children Admitted to the Emergency Department. Pediatr Emerg Care. 2022 Sep 30. doi: 10.1097/PEC.0000000000002854. PMID: 36173338. ↥

  33. Kafali, Biler, Palamar, Ozbaran (2020): Ocular injuries, attention deficit and hyperactivity disorder, and maternal anxiety/depression levels: Is there a link? Chin J Traumatol. 2020 Apr;23(2):71-77. doi: 10.1016/j.cjtee.2019.11.008. PMID: 32201230; PMCID: PMC7156958. n = 79 ↥

  34. Chou IC, Lin CC, Sung FC, Kao CH. (2014): Attention-deficit hyperactivity disorder increases the risk of deliberate self-poisoning: A population-based cohort. Eur Psychiatry. 2014 Oct;29(8):523-7. doi: 10.1016/j.eurpsy.2014.05.006. PMID: 25172157. n = 3.685 ↥

  35. Barkley RA (2002): Major life activity and health outcomes associated with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2002;63 Suppl 12:10-5. PMID: 12562056. ↥ ↥ ↥ ↥ ↥ ↥

  36. Vaa T (2014): ADHD and relative risk of accidents in road traffic: a meta-analysis. Accid Anal Prev. 2014 Jan;62:415-25. doi: 10.1016/j.aap.2013.10.003. PMID: 24238842. METASTUDY ↥ ↥

  37. Skyving, Forsman, Dukic Willstrand, Laflamme, Möller (2021): Medical impairment and road traffic crashes among older drivers in Sweden – A national, population-based, case-control study. Accid Anal Prev. 2021 Oct 23;163:106434. doi: 10.1016/j.aap.2021.106434. PMID: 34700248.) ↥

  38. Mannuzza S, Klein RG, Konig PH, Giampino TL (1989): Hyperactive boys almost grown up. IV. Criminality and its relationship to psychiatric status. Arch Gen Psychiatry. 1989 Dec;46(12):1073-9. doi: 10.1001/archpsyc.1989.01810120015004. PMID: 2589922. ↥

  39. Biederman, Faraone, Spencer, Mick, Monuteaux, Aleardi (2006): Functional impairments in adults with self-reports of diagnosed ADHD: A controlled study of 1001 adults in the community. J Clin Psychiatry. 2006 Apr;67(4):524-40. ↥ ↥ ↥ ↥ ↥ ↥

  40. Yu, Nevado-Holgado, Molero, D’Onofrio, Larsson, Howard, Fazel (2019): Mental disorders and intimate partner violence perpetrated by men towards women: A Swedish population-based longitudinal study. PLoS Med. 2019 Dec 17;16(12):e1002995. doi: 10.1371/journal.pmed.1002995. eCollection 2019 Dec. ↥

  41. Rösler, zitiert von Dlubis-Mertens (2004): ADHS bei Erwachsenen: Riskantes Leben. PP 3, Ausgabe Februar 2004, Seite 76 ↥

  42. Ginsberg, Hirvikoski, Lindefors (2010): Attention deficit hyperactivity disorder (ADHD) among longer-term prison inmates is a prevalent, persistent and disabling disorder. BMC Psychiatry, 10 Art. Nr. 112, zitiert nach Schmidt, Petermann: ADHS über die Lebensspanne – Symptome und neue diagnostische Ansätze, Zeitschrift für Psychiatrie, Psychologie und Psychotherapie, 59 (3), 2011, 227–238, Seite 232, neben dort weiter genannten Studien ↥

  43. Rösler, Retz, Retz-Junginger, Hengesch, Schneider, Supprian, Schwitzgebel, Pinhard, Dovi-Akue, Wender, Thome (2004): Prevalence of attention deficit-/hyperactivity disorder (ADHD) and comorbid disorders in young male prison inmates. European Archives of Psychiatry and Clinical Neuroscience, 254, 365 – 371, n = 183 ↥

  44. Philipsen, Heßlinger, Tebartz van Elst: Aufmerksamkeitsdefizit-Hyperaktivitätsstörung im Erwachsenenalter – Diagnostik, Ätiologie und Therapie (ÜBERSICHTSARBEIT), Deutsches Ärzteblatt, Jg. 105, Heft 17, 25. April 2008, Seite 311 – 317, 313 , Seite 313 ↥

  45. Beaudry, Yu, Långström, Fazel (2020): Mental Disorders Among Adolescents in Juvenile Detention and Correctional Facilities: An Updated Systematic Review and Metaregression Analysis. J Am Acad Child Adolesc Psychiatry. 2020 Feb 5:S0890-8567(20)30061-7. doi: 10.1016/j.jaac.2020.01.015. PMID: 32035113. ↥

  46. Gosden et al. 2003; n = 100, zitiert nach Oehler (2009), Vortrag beim 4. ADHS-Gipfel in Hamburg, 06.-08.02.2009 ↥

  47. Favarino 1988, zitiert nach Oehler (2009), Vortrag beim 4. ADHS-Gipfel in Hamburg, 06.-08.02.2009 ↥

  48. Eyestone und Howell 1994, zitiert nach Oehler (2009), Vortrag beim 4. ADHS-Gipfel in Hamburg, 06.-08.02.2009 ↥

  49. Oehler (2009), Vortrag beim 4. ADHS-Gipfel in Hamburg, 06.-08.02.2009 ↥ ↥

  50. Blocher und Rösler 2002, zitiert nach Oehler (2009), Vortrag beim 4. ADHS-Gipfel in Hamburg, 06.-08.02.2009 ↥

  51. Curran und Fitzgerald 1999, zitiert nach Oehler (2009), Vortrag beim 4. ADHS-Gipfel in Hamburg, 06.-08.02.2009, n = 55, Durchschnittsalter 26,2 J. ↥

  52. Kuzmickaitė, Leskauskas, Gylytė (2019): ADHD-Related Mental Health Issues of Young Adult Male Prisoners in Pravieniškės Correction House-Open Colony (Lithuania). Am J Mens Health. 2019 Jul-Aug;13(4):1557988319870974. doi: 10.1177/1557988319870974. ↥

  53. Asherson, Johansson, Holland, Fahy, Forester, Howitt, Lawrie, Strang, Young, Landau, Thomson (2019): Randomised controlled trial of the short-term effects of OROS-methylphenidate on ADHD symptoms and behavioural outcomes in young male prisoners with attention-deficit/hyperactivity disorder (CIAO-II). Trials. 2019 Dec 2;20(1):663. doi: 10.1186/s13063-019-3705-9. ↥

  54. Satterfield JH, Schell A (1997): A prospective study of hyperactive boys with conduct problems and normal boys: adolescent and adult criminality. J Am Acad Child Adolesc Psychiatry. 1997 Dec;36(12):1726-35. doi: 10.1097/00004583-199712000-00021. PMID: 9401334. ↥

  55. Rasmussen, Gillberg (2000): Natural outcome of ADHD with developmental coordination disorder at age 22 years: a controlled, longitudinal, community-based study. J Am Acad Child Adolesc Psychiatry. 2000 Nov;39(11):1424-31., n = 55 vs. 46; Durchschnittsalter 22 J ↥

  56. Rösler, Retz, Retz-Junginger, Hengesch, Schneider, Supprian, Schwitzgebel, Pinhard, Dovi-Akue, Wender, Thome (2004): Prevalence of attention deficit-/hyperactivity disorder (ADHD) and comorbid disorders in young male prison inmates. European Archives of Psychiatry and Clinical Neuroscience, 254, 365 – 371, zitiert nach Schmidt, Petermann: ADHS über die Lebensspanne – Symptome und neue diagnostische Ansätze, Zeitschrift für Psychiatrie, Psychologie und Psychotherapie, 59 (3), 2011, 227–238, Seite 232 ↥

  57. Engelhardt, Nobes, Pischedda (2019): The Relationship between Adult Symptoms of Attention-Deficit/Hyperactivity Disorder and Criminogenic Cognitions. Brain Sci. 2019 Jun 2;9(6). pii: E128. doi: 10.3390/brainsci9060128. ↥

  58. Lichtenstein, Halldner, Zetterqvist, Sjölander, Serlachius, Fazel, Långström, Larsson (2012): Medication for attention deficit-hyperactivity disorder and criminality. N Engl J Med. 2012 Nov 22;367(21):2006-14. doi: 10.1056/NEJMoa1203241. PMID: 23171097; PMCID: PMC3664186. n = 25.656 ↥ ↥

  59. Miesch, Deister (2019): Die Aufmerksamkeitsdefizit- und Hyperaktivitätsstörung (ADHS) in der Erwachsenenpsychiatrie: Erfassung der ADHS-12-Monatsprävalenz, der Risikofaktoren und Komorbidität bei ADHS. Fortschr Neurol Psychiatr 2019; 87(01): 32-38. DOI: 10.1055/s-0043-119987 ↥

  60. Burleson Daviss (2018): Depressive Disorders in ADHD, S. 91 in: Burleson Daviss (Hrsg.): Moodiness in ADHD – A Clinicians Guide ↥

  61. Soler Artigas, Sánchez-Mora, Rovira, Vilar-Ribó, Ramos-Quiroga, Ribasés (2022): Mendelian randomization analysis for attention deficit/hyperactivity disorder: studying a broad range of exposures and outcomes. Int J Epidemiol. 2022 Jun 12:dyac128. doi: 10.1093/ije/dyac128. PMID: 35690959. ↥ ↥ ↥

  62. Biederman, Ball, Monuteaux, Mick, Spencer, McCreary, Cote, Faraone (2008): New Insights Into the Comorbidity Between ADHD and Major Depression in Adolescent and Young Adult Females, Journal of the American Academy of Child & Adolescent Psychiatry, Volume 47, Issue 4, 2008, Pages 426-434, ISSN 0890-8567, https://doi.org/10.1097/CHI.0b013e31816429d3 ↥

  63. Powell, Riglin, Hammerton, Eyre, Martin, Anney, Thapar, Rice (2020): What explains the link between childhood ADHD and adolescent depression? Investigating the role of peer relationships and academic attainment. Eur Child Adolesc Psychiatry. 2020 Jan 13;10.1007/s00787-019-01463-w. doi: 10.1007/s00787-019-01463-w.. PMID: 31932968. ↥

  64. Zhang, Du Rietz, Kuja-Halkola, Dobrosavljevic, Johnell, Pedersen, Larsson, Chang (2021): Attention-deficit/hyperactivity disorder and Alzheimer’s disease and any dementia: A multi-generation cohort study in Sweden. Alzheimers Dement. 2021 Sep 9. doi: 10.1002/alz.12462. PMID: 34498801. n = 2.132.929 ↥

  65. Leffa DT, Ferrari-Souza JP, Bellaver B, Tissot C, Ferreira PCL, Brum WS, Caye A, Lord J, Proitsi P, Martins-Silva T, Tovo-Rodrigues L, Tudorascu DL, Villemagne VL, Cohen AD, Lopez OL, Klunk WE, Karikari TK, Rosa-Neto P, Zimmer ER, Molina BSG, Rohde LA, Pascoal TA; Alzheimer’s Disease Neuroimaging Initiative (2022): Genetic risk for attention-deficit/hyperactivity disorder predicts cognitive decline and development of Alzheimer’s disease pathophysiology in cognitively unimpaired older adults. Mol Psychiatry. 2022 Dec 8. doi: 10.1038/s41380-022-01867-2. PMID: 36476732. ↥

  66. Becker, Sharma, Callahan (2022): ADHD and Neurodegenerative Disease Risk: A Critical Examination of the Evidence. Front Aging Neurosci. 2022 Jan 25;13:826213. doi: 10.3389/fnagi.2021.826213. PMID: 35145394; PMCID: PMC8822599. REVIEW ↥

  67. Biederman, Ball, Monuteaux, Surman, Johnson, Zeitlin (2007): Are Girls with ADHD at Risk for Eating Disorders? Results from a Controlled, Five-Year Prospective Study. Journal of Developmental & Behavioral Pediatrics: August 2007 – Volume 28 – Issue 4 – p 302-307. doi: 10.1097/DBP.0b013e3180327917 ↥

  68. ZI Mannheim (Download 2019): Flyer Angststörungen ↥

  69. Loskutova, Waterman, Callen, Staton, Bullard, Shields (2020): Knowledge, Attitudes, and Practice Patterns of Health Professionals Toward Medical and Non-medical Stimulant Use by Young Adults. J Am Board Fam Med. 2020 Jan-Feb;33(1):59-70. doi: 10.3122/jabfm.2020.01.190071. ↥ ↥

  70. Jaisoorya, Desai, Nair, Rani, Menon, Thennarasu (2019): Association of Childhood Attention Deficit Hyperactivity Disorder Symptoms with Academic and Psychopathological Outcomes in Indian College Students: a Retrospective Survey. East Asian Arch Psychiatry. 2019 Dec;2 9(124):124-128. doi: 10.12809/eaap1771. n = 5.145 ↥

  71. Du Rietz, Brikell, Butwicka, Leone, Chang, Cortese, D’Onofrio, Hartman, Lichtenstein, Faraone, Kuja-Halkola, Larsson (2021): Mapping phenotypic and aetiological associations between ADHD and physical conditions in adulthood in Sweden: a genetically informed register study. Lancet Psychiatry. 2021 Jul 6:S2215-0366(21)00171-1. doi: 10.1016/S2215-0366(21)00171-1. PMID: 34242595. n = 4.789.799 ↥

  72. Merzon, Israel, Ashkenazi, Rotem, Schneider, Faraone, Biederman, Green, Golan-Cohen, Vinker, Weizman, Manor (2022): IlanAttention-Deficit/Hyperactivity Disorder Is Associated With Increased Rates of Childhood Infectious Diseases: A Population-based Case-Control Study. J Am Acad Child Adolesc Psychiatry. 2022 Aug 19:S0890-8567(22)01243-6. doi: 10.1016/j.jaac.2022.06.018. PMID: 36007815. n = 56.000 ↥

  73. Howard, Kennedy, Mitchell, Sibley, Hinshaw, Arnold, Roy, Stehli, Swanson, Molina (2019):Early substance use in the pathway from childhood attention-deficit/hyperactivity disorder (ADHD) to young adult substance use: Evidence of statistical mediation and substance specificity. Psychol Addict Behav. 2019 Dec 30. doi: 10.1037/adb0000542. ↥ ↥

  74. Elkins, Saunders, Malone, Keyes, Samek, McGue, Iacono (2017): Increased Risk of Smoking in Female Adolescents Who Had Childhood ADHD. Am J Psychiatry. 2018 Jan 1;175(1):63-70. doi: 10.1176/appi.ajp.2017.17010009. PMID: 28838251; PMCID: PMC5756118. ↥

  75. Kaplan, Marcell, Kaplan, Cohen (2021): Association between e-cigarette use and parents’ report of attention deficit hyperactivity disorder among US youth. Tob Induc Dis. 2021 Jun 4;19:44. doi: 10.18332/tid/136031. PMID: 34140843; PMCID: PMC8176894. n = 11.801 ↥

  76. Charach, Yeung, Climans, Lillie (2011): Childhood Attention-Deficit/Hyperactivity Disorder and Future Substance Use Disorders: Comparative Meta-Analyses, Journal of the American Academy of Child & Adolescent Psychiatry, Volume 50, Issue 1, 2011, Pages 9-21, ISSN 0890-8567, https://doi.org/10.1016/j.jaac.2010.09.019 ↥

  77. van Amsterdam, van der Velde, Schulte, van den Brink (2018): Causal Factors of Increased Smoking in ADHD: A Systematic Review. Subst Use Misuse. 2018 Feb 23;53(3):432-445. doi: 10.1080/10826084.2017.1334066. PMID: 29039714. REVIEW ↥ ↥ ↥

  78. Groenman, Oosterlaan, Rommelse, Franke, Roeyers, Oades, Sergeant, Buitelaar, Faraone (2013), Follow‐up of substance use in ADHD. Addiction, 108: 1503-1511. doi:10.1111/add.12188, n = 1017 ↥ ↥

  79. Pal, Balhara (2016): A Review of Impact of Tobacco Use on Patients with Co-occurring Psychiatric Disorders. Tob Use Insights. 2016 Mar 10;9:7-12. doi: 10.4137/TUI.S32201. PMID: 26997871; PMCID: PMC4788174. REVIEW ↥ ↥

  80. Zamboni, Marchetti, Congiu, Giordano, Fusina, Carli, Centoni, Verlato, Lugoboni (2021): ASRS Questionnaire and Tobacco Use: Not Just a Cigarette. A Screening Study in an Italian Young Adult Sample. Int J Environ Res Public Health. 2021 Mar 12;18(6):2920. doi: 10.3390/ijerph18062920. PMID: 33809225. n = 389 ↥

  81. Berg, Haardörfer, Lanier, Childs, Foster, Getachew, Windle (2020): Tobacco use trajectories in young adults: Analyses of predictors across systems levels. Nicotine Tob Res. 2020 Mar 14:ntaa048. doi: 10.1093/ntr/ntaa048. PMID: 32170324. n = 2.592 ↥

  82. Kuppa, Maysun (2019): Risk of Alcohol Abuse in Humans with Attention-deficit/Hyperactivity Disorder Symptoms. Cureus. 2019 Oct 25;11(10):e5996. doi: 10.7759/cureus.5996. ↥

  83. Walsh CJ, Rosenberg SL, Hale EW (2022): Obstetric complications in mothers with ADHD. Front Reprod Health. 2022 Nov 7;4:1040824. doi: 10.3389/frph.2022.1040824. PMID: 36419963; PMCID: PMC9678343. ↥

  84. Du R, Zhou Y, You C, Liu K, King DA, Liang ZS, Ranson JM, Llewellyn DJ, Huang J, Zhang Z. Attention-deficit/hyperactivity disorder and ischemic stroke: A Mendelian randomization study. Int J Stroke. 2022 Jul 6:17474930221108272. doi: 10.1177/17474930221108272. PMID: 35670701. ↥

  85. Hua, Huang, Hsu, Bai, Su, Tsai, Li, Lin, Chen, Chen (2020): Early Pregnancy Risk Among Adolescents With ADHD: A Nationwide Longitudinal Study. J Atten Disord. 2020 Jan 23;1087054719900232. doi: 10.1177/1087054719900232. PMID: 31971056. ↥ ↥

  86. Christiansen, Labriola, Kirkeskov, Lund (2021): The impact of childhood diagnosed ADHD versus controls without ADHD diagnoses on later labour market attachment-a systematic review of longitudinal studies. Child Adolesc Psychiatry Ment Health. 2021 Jun 23;15(1):34. doi: 10.1186/s13034-021-00386-2. PMID: 34162422; PMCID: PMC8220843. METASTUDY ↥ ↥

  87. Fleming M, Fitton CA, Steiner MFC, McLay JS, Clark D, King A, Mackay DF, Pell JP (2017): Educational and Health Outcomes of Children Treated for Attention-Deficit/Hyperactivity Disorder. JAMA Pediatr. 2017 Jul 3;171(7):e170691. doi: 10.1001/jamapediatrics.2017.0691. PMID: 28459927; PMCID: PMC6583483. n = 766.244 ↥ ↥ ↥ ↥

  88. Rushton, Giallo, Efron (2019): ADHD and emotional engagement with school in the primary years: Investigating the role of student-teacher relationships. Br J Educ Psychol. 2019 Oct 26. doi: 10.1111/bjep.12316. n = 489 ↥

  89. Hayashi, Suzuki, Saga, Arai, Igarashi, Tokumasu, Ota, Yamada, Takashio, Iwanami (2019): Clinical Characteristics of Women with ADHD in Japan. Neuropsychiatr Dis Treat. 2019 Dec 4;15:3367-3374. doi: 10.2147/NDT.S232565. eCollection 2019. n = 335 ↥ ↥

  90. Barkley, Murphy (1998): ADHD: A Clinical Workbook; Milwaukee Young Adult Outcome Study, zitiert nach Oehler (2009), Vortrag beim 4. ADHS-Gipfel in Hamburg, 06.-08.02.2009 ↥ ↥ ↥

  91. Schwörer, Reinelt, Petermann, Petermann (2020): Influence of executive functions on the self-reported health-related quality of life of children with ADHD. Qual Life Res. 2020 Jan 3. doi: 10.1007/s11136-019-02394-4. ↥ ↥

  92. Ghajar, DeBoer (2020): Children With Attention-Deficit/Hyperactivity Disorder Are at Increased Risk for Slowed Growth and Short Stature in Early Childhood. Clin Pediatr (Phila). 2020 Feb 1:9922820902437. doi: 10.1177/0009922820902437. PMID: 32009447. n = 7.603 ↥

  93. Stern, Agnew-Blais, Danese, Fisher, Matthews, Polanczyk, Wertz, Arseneault (2020): Associations between ADHD and emotional problems from childhood to young adulthood: a longitudinal genetically sensitive study. J Child Psychol Psychiatry. 2020 Feb 29:10.1111/jcpp.13217. doi: 10.1111/jcpp.13217. PMID: 32112575; PMCID: PMC7483180. n = 2.232 ↥

  94. Biederman et al. 2006, zitiert nach Oehler (2009), Vortrag beim 4. ADHS-Gipfel in Hamburg, 06.-08.02.2009 ↥

  95. Schmidt, Waldmann, Petermann, Brähler (2010): Wie stark sind Erwachsene mit ADHS und komorbiden Störungen in ihrer gesundheitsbezogenen Lebensqualität beeinträchtigt? Zeitschrift für Psychiatrie, Psychologie und Psychotherapie, 58, 9–21, zitiert nach Schmidt, Petermann: ADHS über die Lebensspanne – Symptome und neue diagnostische Ansätze, Zeitschrift für Psychiatrie, Psychologie und Psychotherapie, 59 (3), 2011, 227–238, Seite 229 ↥

  96. Baumgarten, Cohrdes, Schienkiewitz, Thamm, Meyrose, Ravens-Sieberer (2019): [Health-related quality of life and its relation to chronic diseases and mental health problems among children and adolescents : Results from KiGGS Wave 2].[Article in German] Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2019 Sep 16. doi: 10.1007/s00103-019-03006-9. ↥

  97. Döpfner, Mandler, Breuer, Schürmann, Dose, Walter, von Wirth (2020): Children with Attention-Deficit/Hyperactivity Disorder Grown Up: An 18-Year Follow-Up after Multimodal Treatment. J Atten Disord. 2020 Aug 10:1087054720948133. doi: 10.1177/1087054720948133. PMID: 32772881. n = 70 ↥

  98. Battison EAJ, Brown PCM, Holley AL, Wilson AC (2023): Associations between Chronic Pain and Attention-Deficit Hyperactivity Disorder (ADHD) in Youth: A Scoping Review. Children (Basel). 2023 Jan 11;10(1):142. doi: 10.3390/children10010142. PMID: 36670692; PMCID: PMC9857366. REVIEW ↥

  99. Chang, Ghirardi, Quinn, Asherson, D’Onofrio, Larsson (2019): Risks and Benefits of Attention-Deficit/Hyperactivity Disorder Medication on Behavioral and Neuropsychiatric Outcomes: A Qualitative Review of Pharmacoepidemiology Studies Using Linked Prescription Databases. Biol Psychiatry. 2019 Sep 1;86(5):335-343. doi: 10.1016/j.biopsych.2019.04.009. METASTUDY ↥

  100. Boland, DiSalvo, Fried, Woodworth, Wilens, Faraone. Biederman (2020): A literature review and meta-analysis on the effects of ADHD medications on functional outcomes. J Psychiatr Res. 2020 Jan 27;123:21-30. doi: 10.1016/j.jpsychires.2020.01.006. PMID: 32014701. METASTUDY ↥

  101. de Faria, Duarte, Ferreira, da Silveira, Menezes de Pádua, Perini (2021): “Real-world” effectiveness of methylphenidate in improving the academic achievement of Attention-Deficit Hyperactivity Disorder diagnosed students-A systematic review. J Clin Pharm Ther. 2021 Jul 13. doi: 10.1111/jcpt.13486. PMID: 34254328. METASTUDY ↥

  102. Mechler, Banaschewski, Hohmann, Häge (2021): Evidence-based pharmacological treatment options for ADHD in children and adolescents. Pharmacol Ther. 2021 Jun 23:107940. doi: 10.1016/j.pharmthera.2021.107940. PMID: 34174276. ↥

  103. Chang, Quinn, O’Reilly, Sjölander, Hur, Gibbons, Larsson, D’Onofrio (2019): Medication for Attention-Deficit/Hyperactivity Disorder and Risk for Suicide Attempts. Biol Psychiatry. 2019 Dec 13;S0006-3223(19)31920-1. doi: 10.1016/j.biopsych.2019.12.003. PMID: 31987492. n = 3.874.728 ↥

  104. Chen, Sjölander, Runeson, D’Onofrio, Lichtenstein, Larsson (2014): Drug treatment for attention-deficit/hyperactivity disorder and suicidal behaviour: register based study. BMJ. 2014 Jun 18;348:g3769. doi: 10.1136/bmj.g3769. PMID: 24942388; PMCID: PMC4062356. n = 37.936 ↥ ↥

  105. Siffel, DerSarkissian, Kponee-Shovein, Spalding, Gu, Cheng, Duh (2020): Suicidal ideation and attempts in the United States of America among stimulant-treated, non-stimulant-treated, and untreated patients with a diagnosis of attention-deficit/hyperactivity disorder. J Affect Disord. 2020 Jan 22;266:109-119. doi: 10.1016/j.jad.2020.01.075. PMID: 32063553. n = 797.189 ↥

  106. Liang SH, Yang YH, Kuo TY, Liao YT, Lin TC, Lee Y, McIntyre, Kelsen, Wang TN, Chen VC (2018): Suicide risk reduction in youths with attention-deficit/hyperactivity disorder prescribed methylphenidate: A Taiwan nationwide population-based cohort study. Res Dev Disabil. 2018 Jan;72:96-105. doi: 10.1016/j.ridd.2017.10.023. PMID: 29121517. ↥ ↥

  107. Man, Coghill, Chan, Lau, Hollis, Liddle, Banaschewski, McCarthy, Neubert, Sayal, Ip, Schuemie, Sturkenboom, Sonuga-Barke, Buitelaar, Carucci, Zuddas, Kovshoff, Garas, Nagy, Inglis, Konrad, Häge, Rosenthal, Wong (2017). Association of Risk of Suicide Attempts With Methylphenidate Treatment. JAMA Psychiatry. 2017 Oct 1;74(10):1048-1055. doi: 10.1001/jamapsychiatry.2017.2183. PMID: 28746699; PMCID: PMC5710471. n = 25.629 ↥

  108. Ghirardi, Larsson, Chang, Chen, Quinn, Hur, Gibbons, D’Onofrio (2019): Attention-Deficit/Hyperactivity Disorder Medication and Unintentional Injuries in Children and Adolescents. J Am Acad Child Adolesc Psychiatry. 2019 Jul 11. pii: S0890-8567(19)30452-6. doi: 10.1016/j.jaac.2019.06.010. n = 1.968.146 AD(H)S-Betroffene ↥

  109. Rockhill (2019): A Spoonful of Injury Prevention Makes the ADHD Medicine Go Down. J Am Acad Child Adolesc Psychiatry. 2019 Dec 6. pii: S0890-8567(19)32224-5. doi: 10.1016/j.jaac.2019.11.019. ↥

  110. Dalsgaard, Leckman, Mortensen, Nielsen, Simonsen (2015): Effect of drugs on the risk of injuries in children with attention deficit hyperactivity disorder: a prospective cohort study. Lancet Psychiatry. 2015 Aug;2(8):702-709. doi: 10.1016/S2215-0366(15)00271-0. PMID: 26249301. n = 700.000 / 4.557 ↥

  111. Liao YT, Yang YH, Kuo TY, Liang HY, Huang KY, Wang TN, Lee Y, McIntyre RS, Chen VC (2018): Dosage of methylphenidate and traumatic brain injury in ADHD: a population-based study in Taiwan. Eur Child Adolesc Psychiatry. 2018 Mar;27(3):279-288. doi: 10.1007/s00787-017-1042-7. PMID: 28856464. n = 124.438 ↥

  112. Ghirardi, Chen, Chang, Kuja-Halkola, Skoglund, Quinn, D’Onofrio, Larsson (2019): Use of medication for attention-deficit/hyperactivity disorder and risk of unintentional injuries in children and adolescents with co-occurring neurodevelopmental disorders. J Child Psychol Psychiatry. 2019 Oct 18. doi: 10.1111/jcpp.13136. n = 9.421 ↥

  113. Chen VC, Chan HL, Wu SI, Lu ML, Dewey, Stewart, Lee CT (2020): Methylphenidate and mortality in children with attention-deficit hyperactivity disorder: population-based cohort study. Br J Psychiatry. 2020 Jul 14:1-9. doi: 10.1192/bjp.2020.129. PMID: 32662370. ↥

  114. McCarthy, Cranswick, Potts, Taylor, Wong (2009): Mortality associated with attention-deficit hyperactivity disorder (ADHD) drug treatment: a retrospective cohort study of children, adolescents and young adults using the general practice research database. Drug Saf. 2009;32(11):1089-96. doi: 10.2165/11317630-000000000-00000. ↥

  115. Chang Z, D’Onofrio, Quinn, Lichtenstein, Larsson (2016): Medication for Attention-Deficit/Hyperactivity Disorder and Risk for Depression: A Nationwide Longitudinal Cohort Study. Biol Psychiatry. 2016 Dec 15;80(12):916-922. doi: 10.1016/j.biopsych.2016.02.018. PMID: 27086545; PMCID: PMC4995143. ↥

  116. Sidrak JP, Blaakman SR, Hale EW (2023): Fracture rates by medication type in attention-deficit/hyperactive disorder. Front Surg. 2023 Feb 15;10:973266. doi: 10.3389/fsurg.2023.973266. PMID: 36874450; PMCID: PMC9975348. n = 783.888 ↥

  117. DeFroda, Quinn, Yang, Daniels, Owens (2020): The effects of methylphenidate on stress fractures in patients’ ages 10-29: a national database study. Phys Sportsmed. 2020 Feb 13:1-5. doi: 10.1080/00913847.2020.1725400. PMID: 32013692. n = 861.029 ↥

  118. Chen VC, Yang YH, Liao YT, Kuo TY, Liang HY, Huang KY, Huang YC, Lee Y, McIntyre RS, Lin TC (2017): The association between methylphenidate treatment and the risk for fracture among young ADHD patients: A nationwide population-based study in Taiwan. PLoS One. 2017 Mar 15;12(3):e0173762. doi: 10.1371/journal.pone.0173762. Erratum in: PLoS One. 2017 Apr 6;12 (4):e0175617. PMID: 28296941; PMCID: PMC5351966. ↥

  119. Ghirardi, Chen, Chang, Kuja-Halkola, Skoglund, Quinn, D’Onofrio, Larsson (2020): Use of medication for attention-deficit/hyperactivity disorder and risk of unintentional injuries in children and adolescents with co-occurring neurodevelopmental disorders. J Child Psychol Psychiatry. 2020 Feb;61(2):140-147. doi: 10.1111/jcpp.13136. PMID: 31625605; PMCID: PMC6980200. n = 9.421 ↥ ↥

  120. Ruiz-Goikoetxea, Cortese, Aznarez-Sanado, Magallón, Alvarez Zallo, Luis, de Castro-Manglano, Soutullo, Arrondo (2018): Risk of unintentional injuries in children and adolescents with ADHD and the impact of ADHD medications: A systematic review and meta-analysis. Neurosci Biobehav Rev. 2018 Jan;84:63-71. doi: 10.1016/j.neubiorev.2017.11.007. PMID: 29162520. n = 13.254, METASTUDY ↥

  121. Gao, Man, Chan, Chui, Li, Coghill, Hon, Tse, Lum, Wong, Ip, Wong (2021): Treatment with Methylphenidate for Attention Deficit Hyperactivity Disorder (ADHD) and the Risk of All-Cause Poisoning in Children and Adolescents: A Self-Controlled Case Series Study. CNS Drugs. 2021 Jul;35(7):769-779. doi: 10.1007/s40263-021-00824-x. PMID: 34283391; PMCID: PMC8310501. ↥

  122. Man, Chan EW, Coghill, Douglas, Ip, Leung LP, Tsui MS, Wong WH, Wong IC (2015): Methylphenidate and the risk of trauma. Pediatrics. 2015 Jan;135(1):40-8. doi: 10.1542/peds.2014-1738. PMID: 25511122. n = 17.381 ↥

  123. Chen VC, Yang YH, Yu Kuo T, Lu ML, Tseng WT, Hou TY, Yeh JY, Lee CT, Chen YL, Lee MJ, Dewey, Gossop (2020): Methylphenidate and the risk of burn injury among children with attention-deficit/hyperactivity disorder. Epidemiol Psychiatr Sci. 2020 Jul 20;29:e146. doi: 10.1017/S2045796020000608. PMID: 32686635; PMCID: PMC7372158. n = 90.634 ↥

  124. Chang Z, Lichtenstein, D’Onofrio, Sjölander, Larsson (2014): Serious transport accidents in adults with attention-deficit/hyperactivity disorder and the effect of medication: a population-based study. JAMA Psychiatry. 2014 Mar;71(3):319-25. doi: 10.1001/jamapsychiatry.2013.4174. PMID: 24477798; PMCID: PMC3949159. ↥ ↥

  125. Chang Z, Quinn, Hur, Gibbons, Sjölander, Larsson, D’Onofrio (2017): Association Between Medication Use for Attention-Deficit/Hyperactivity Disorder and Risk of Motor Vehicle Crashes. JAMA Psychiatry. 2017 Jun 1;74(6):597-603. doi: 10.1001/jamapsychiatry.2017.0659. PMID: 28492937; PMCID: PMC5539840. n = 2.319.450 ↥ ↥

  126. Chen MH, Hsu JW, Huang KL, Bai YM, Ko NY, Su TP, Li CT, Lin WC, Tsai SJ, Pan TL, Chang WH, Chen TJ (2018): Sexually Transmitted Infection Among Adolescents and Young Adults With Attention-Deficit/Hyperactivity Disorder: A Nationwide Longitudinal Study. J Am Acad Child Adolesc Psychiatry. 2018 Jan;57(1):48-53. doi: 10.1016/j.jaac.2017.09.438. PMID: 29301669. n = 89.000 ↥

  127. Hesapcıoglu, Kandemir (2020): Association of methylphenidate use and traditional/cyberbullying. Pediatr Int. 2020 Feb 5:10.1111/ped.14185. doi: 10.1111/ped.14185. PMID: 32022957. ↥

  128. Schoenfelder, Faraone, Kollins (2014): Stimulant treatment of ADHD and cigarette smoking: a meta-analysis. Pediatrics. 2014 Jun;133(6):1070-80. doi: 10.1542/peds.2014-0179. PMID: 24819571; PMCID: PMC4531271. 14 Studien, n =2.360; METASTUDY ↥

  129. Chang, Lichtenstein, Halldner, D’Onofrio, Serlachius, Fazel, Långström, Larsson (2014): Stimulant ADHD medication and risk for substance abuse. J Child Psychol Psychiatry. 2014 Aug;55(8):878-85. doi: 10.1111/jcpp.12164. PMID: 25158998; PMCID: PMC4147667. n = 38.753 ↥

  130. Humphreys, Eng T, Lee SS (2013): Stimulant medication and substance use outcomes: a meta-analysis. JAMA Psychiatry. 2013 Jul;70(7):740-9. doi: 10.1001/jamapsychiatry.2013.1273. PMID: 23754458; PMCID: PMC6688478. METAANALYSE ↥

  131. Mohr-Jensen, Müller Bisgaard, Boldsen, Steinhausen (2019): Attention-Deficit/Hyperactivity Disorder in Childhood and Adolescence and the Risk of Crime in Young Adulthood in a Danish Nationwide Study. J Am Acad Child Adolesc Psychiatry. 2019 Apr;58(4):443-452. doi: 10.1016/j.jaac.2018.11.016. PMID: 30768385. n = 4.200 ↥

  132. Jangmo, Stålhandske, Chang Z, Chen Q, Almqvist, Feldman, Bulik, Lichtenstein, D’Onofrio, Kuja-Halkola, Larsson (2019): Attention-Deficit/Hyperactivity Disorder, School Performance, and Effect of Medication. J Am Acad Child Adolesc Psychiatry. 2019 Apr;58(4):423-432. doi: 10.1016/j.jaac.2018.11.014. PMID: 30768391; PMCID: PMC6541488. n = 657.720 ↥

  133. Lu Y, Sjölander, Cederlöf, D’Onofrio, Almqvist, Larsson, Lichtenstein (2017): Association Between Medication Use and Performance on Higher Education Entrance Tests in Individuals With Attention-Deficit/Hyperactivity Disorder. JAMA Psychiatry. 2017 Aug 1;74(8):815-822. doi: 10.1001/jamapsychiatry.2017.1472. PMID: 28658471; PMCID: PMC5710548. n = 61.000 ↥

  134. Keilow, Holm, Fallesen (2018): Medical treatment of Attention Deficit/Hyperactivity Dis)order (ADHD) and children’s academic performance. PLoS One. 2018 Nov 29;13(11):e0207905. doi: 10.1371/journal.pone.0207905. PMID: 30496240; PMCID: PMC6264851. n = 6.400 ↥

  135. Tsujii, Okada, Usami, Kuwabara, Fujita, Negoro, Kawamura, Iida, Saito (2020): Effect of Continuing and Discontinuing Medications on Quality of Life After Symptomatic Remission in Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-Analysis. J Clin Psychiatry. 2020 Mar 24;81(3):19r13015. doi: 10.4088/JCP.19r13015. PMID: 32237294. n = 1.463 METASTUDY ↥

  136. Biederman, DiSalvo, Fried, Woodworth, Biederman, Faraone (2019): Quantifying the Protective Effects of Stimulants on Functional Outcomes in Attention-Deficit/Hyperactivity Disorder: A Focus on Number Needed to Treat Statistic and Sex Effects, Journal of Adolescent Health, 2019, ISSN 1054-139X, https://doi.org/10.1016/j.jadohealth.2019.05.015. ↥

  137. Marchetti A, Magar R, Lau H, Murphy EL, Jensen PS, Conners CK, Findling R, Wineburg E, Carotenuto I, Einarson TR, Iskedjian M (2001): Pharmacotherapies for attention-deficit/hyperactivity disorder: expected-cost analysis. Clin Ther. 2001 Nov;23(11):1904-21. doi: 10.1016/s0149-2918(00)89086-4. PMID: 11768842. ↥

  138. Jennum P, Hastrup LH, Ibsen R, Kjellberg J, Simonsen E (2020): Welfare consequences for people diagnosed with attention deficit hyperactivity disorder (ADHD): A matched nationwide study in Denmark. Eur Neuropsychopharmacol. 2020 Aug;37:29-38. doi: 10.1016/j.euroneuro.2020.04.010. PMID: 32682821. n = 456.421 ↥ ↥ ↥ ↥ ↥

  139. Leibson, Katusic, Barbaresi, Ransom, O’Brien (2001): Use and Costs of Medical Care for Children and Adolescents With and Without Attention-Deficit/Hyperactivity Disorder. JAMA. 2001;285(1):60-66. doi:10.1001/jama.285.1.60 ↥

  140. Le HH, Hodgkins P, Postma MJ, Kahle J, Sikirica V, Setyawan J, Erder MH, Doshi JA (2014): Economic impact of childhood/adolescent ADHD in a European setting: the Netherlands as a reference case. Eur Child Adolesc Psychiatry. 2014 Jul;23(7):587-98. doi: 10.1007/s00787-013-0477-8. PMID: 24166532; PMCID: PMC4077218. ↥ ↥ ↥

  141. Secnik K, Swensen A, Lage MJ (2005): Comorbidities and costs of adult patients diagnosed with attention-deficit hyperactivity disorder. Pharmacoeconomics. 2005;23(1):93-102. doi: 10.2165/00019053-200523010-00008. PMID: 15693731. n = 4.504 ↥

  142. Schein J, Adler LA, Childress A, Gagnon-Sanschagrin P, Davidson M, Kinkead F, Cloutier M, Guérin A, Lefebvre P (2022): Economic burden of attention-deficit/hyperactivity disorder among adults in the United States: a societal perspective. J Manag Care Spec Pharm. 2022 Feb;28(2):168-179. doi: 10.18553/jmcp.2021.21290. PMID: 34806909. ↥ ↥ ↥ ↥

  143. De Ridder A, De Graeve D (2003): Healthcare use, social burden and costs of children with and without ADHD in Flanders, Belgium. Clin Drug Investig. 2006;26(2):75-90. doi: 10.2165/00044011-200626020-00003. PMID: 17163238. ↥

  144. Chorozoglou M, Smith E, Koerting J, Thompson MJ, Sayal K, Sonuga-Barke EJ (2015): Preschool hyperactivity is associated with long-term economic burden: evidence from a longitudinal health economic analysis of costs incurred across childhood, adolescence and young adulthood. J Child Psychol Psychiatry. 2015 Sep;56(9):966-75. doi: 10.1111/jcpp.12437. PMID: 26072954; PMCID: PMC4744758. n = 258 ↥

  145. Zhao, Page, Altszuler, Pelham III, Kipp, Gnagy, Coxe, Schatz, Merrill, Macphee, Pelham Jr. (2019): Family Burden of Raising a Child with ADHD. Journal of Abnormal Child Psychology. August 2019, Volume 47, Issue 8, pp 1327–1338 ↥

  146. National Alliance for Caregiving (NAC). On pins and needles: caregivers of adults with mental illness. February 2016. ↥

  147. National Alliance for Caregiving (NAC). Caregiving in the U.S.: 2015 report. June 2015. ↥

  148. Doshi JA, Hodgkins P, Kahle J, Sikirica V, Cangelosi MJ, Setyawan J, Erder MH, Neumann PJ (2012): Economic impact of childhood and adult attention-deficit/hyperactivity disorder in the United States. J Am Acad Child Adolesc Psychiatry. 2012 Oct;51(10):990-1002.e2. doi: 10.1016/j.jaac.2012.07.008. PMID: 23021476. REVIEW ↥ ↥

  149. Kessler RC, Adler L, Ames M, Barkley RA, Birnbaum H, Greenberg P, Johnston JA, Spencer T, Ustün TB (2005): The prevalence and effects of adult attention deficit/hyperactivity disorder on work performance in a nationally representative sample of workers. J Occup Environ Med. 2005 Jun;47(6):565-72. doi: 10.1097/01.jom.0000166863.33541.39. PMID: 15951716. ↥

  150. Jangmo A, Kuja-Halkola R, Pérez-Vigil A, Almqvist C, Bulik CM, D’Onofrio B, Lichtenstein P, Ahnemark E, Werner-Kiechle T, Larsson H (2021): Attention-deficit/hyperactivity disorder and occupational outcomes: The role of educational attainment, comorbid developmental disorders, and intellectual disability. PLoS One. 2021 Mar 17;16(3):e0247724. doi: 10.1371/journal.pone.0247724. PMID: 33730071; PMCID: PMC7968636. n = 1,2 Mio ↥ ↥

  151. Sobanski E, Brüggemann D, Alm B, Kern S, Deschner M, Schubert T, Philipsen A, Rietschel M (2007): Psychiatric comorbidity and functional impairment in a clinically referred sample of adults with attention-deficit/hyperactivity disorder (ADHD). Eur Arch Psychiatry Clin Neurosci. 2007 Oct;257(7):371-7. doi: 10.1007/s00406-007-0712-8. PMID: 17902010. n = 140 ↥

  152. Dalsgaard S, Østergaard SD, Leckman JF, Mortensen PB, Pedersen MG (2015): Mortality in children, adolescents, and adults with attention deficit hyperactivity disorder: a nationwide cohort study. Lancet. 2015 May 30;385(9983):2190-6. doi: 10.1016/S0140-6736(14)61684-6. PMID: 25726514. ↥

  153. Swensen A, Birnbaum HG, Ben Hamadi R, Greenberg P, Cremieux PY, Secnik K (2004): Incidence and costs of accidents among attention-deficit/hyperactivity disorder patients. J Adolesc Health. 2004 Oct;35(4):346.e1-9. PMID: 15830457. n > 100.000 ↥

  154. Schöffski O, Sohn S, Happich M (2008): Die gesamtgesellschaftliche Belastung durch die hyperkinetische Störung (HKS) bzw. Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (ADHS) [Overall burden to society caused by hyperkinetic syndrome (HKS) and attention deficit hyperactivity disorder (ADHD)]. Gesundheitswesen. 2008 Jul;70(7):398-403. German. doi: 10.1055/s-0028-1082049. PMID: 18729028. ↥

  155. Schlander M, Trott GE, Schwarz O. Gesundheitsökonomie der Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung in Deutschland Teil 1: Versorgungsepidemiologie und Krankheitskosten [The health economics of attention deficit hyperactivity disorder in Germany. Part 1: Health care utilization and cost of illness]. Nervenarzt. 2010 Mar;81(3):289-300. German. doi: 10.1007/s00115-009-2888-9. PMID: 20232510. ↥

  156. Hong M, Park B, Lee SM, Bahn GH, Kim MJ, Park S, Oh IH, Park H (2020): Economic Burden and Disability-Adjusted Life Years (DALYs) of Attention Deficit/Hyperactivity Disorder. J Atten Disord. 2020 Apr;24(6):823-829. doi: 10.1177/1087054719864632. PMID: 31364445. ↥

  157. Pelham, Page, Altszuler, Gnagy, Molina, Pelham (2019): The long-term financial outcome of children diagnosed with ADHD. J Consult Clin Psychol. 2019 Dec 2. doi: 10.1037/ccp0000461. n = 604 ↥

  158. Daley, Jacobsen, Lange, Sørensen, Walldorf (2019): The economic burden of adult attention deficit hyperactivity disorder: A sibling comparison cost analysis. Eur Psychiatry. 2019 Jul 6;61:41-48. doi: 10.1016/j.eurpsy.2019.06.011. n = 420 Zwillingspaare ↥ ↥

  159. Biederman J, Faraone SV (2006): The effects of attention-deficit/hyperactivity disorder on employment and household income. MedGenMed. 2006 Jul 18;8(3):12. PMID: 17406154; PMCID: PMC1781280. n = 1.000 ↥

  160. Kotsopoulos N, Connolly MP, Sobanski E, Postma MJ (2013) The fiscal consequences of ADHD in Germany: a quantitative analysis based on differences in educational attainment and lifetime earnings. J Ment Health Policy Econ. 2013 Mar;16(1):27-33. PMID: 23676413. ↥

  161. Shea, Perera, Mills (2019): Towards a fuller assessment of the economic benefits of reducing air pollution from fossil fuel combustion: Per-case monetary estimates for children’s health outcomes. Environ Res. 2019 Dec 9;182:109019. doi: 10.1016/j.envres.2019.109019. ↥

  162. Sciberras E, Streatfeild J, Ceccato T, Pezzullo L, Scott JG, Middeldorp CM, Hutchins P, Paterson R, Bellgrove MA, Coghill D (2022): Social and Economic Costs of Attention-Deficit/Hyperactivity Disorder Across the Lifespan. J Atten Disord. 2022 Jan;26(1):72-87. doi: 10.1177/1087054720961828. PMID: 33047627. ↥

  163. Daley D, Jacobsen RH, Lange AM, Sørensen A, Walldorf J (2019): The economic burden of adult attention deficit hyperactivity disorder: A sibling comparison cost analysis. Eur Psychiatry. 2019 Sep;61:41-48. doi: 10.1016/j.eurpsy.2019.06.011. PMID: 31288209. n = 420 Zwillingspaare ↥

  164. Schein J, Adler LA, Childress A, Cloutier M, Gagnon-Sanschagrin P, Davidson M, Kinkead F, Guerin A, Lefebvre P (2022): Economic burden of attention-deficit/hyperactivity disorder among children and adolescents in the United States: a societal perspective. J Med Econ. 2022 Jan-Dec;25(1):193-205. doi: 10.1080/13696998.2022.2032097. PMID: 35068300. ↥

  165. Pelham WE, Foster EM, Robb JA (2007): The economic impact of attention-deficit/hyperactivity disorder in children and adolescents. Ambul Pediatr. 2007 Jan-Feb;7(1 Suppl):121-31. doi: 10.1016/j.ambp.2006.08.002. PMID: 17261491. ↥